期刊文献+

白细胞介素-21在慢性乙型肝炎病毒感染中的作用 被引量:7

The roles of interleukin-21 in chronic hepatitis B virus infection
原文传递
导出
摘要 细胞因子网络是炎症及免疫应答反应的重要效应因子,特别对于获得性免疫网络的构成起到了重要的作用。近年来,以细胞因子为切入点,探讨慢性感染性疾病的发病机制、诊断、预防和治疗策略成为重要的研究方向,如白细胞介素(IL)-28B在丙型肝炎(丙肝)抗病毒治疗[1]、IL-17在重度肝。 Cytokines play important roles in initiating and shaping pathologic responses in chronic viral infection.Recent studies indicate that interleukin(IL)-21,a cytokine produced mostly by activated CD4+ T cells and natural killer cells,regulates activation,proliferation,and survival of both CD4+ T cells and B cells,modulates the functional activity of CD8+ T cells and NK cells and controls the differentiation of inducible Treg and counteracts their suppressive properties on effector T cells.High level of IL-21 is correlated with HBV replication repression and HBeAg sero-conversion in chronic hepatitis B.This review focuses on the critical roles of IL-21 in chronic hepatitis B virus(HBV) infection including HBV-related acute-on-chronic liver failure.
出处 《中国病毒病杂志》 CAS 2012年第3期169-172,共4页 Chinese Journal of Viral Diseases
基金 国家自然科学基金(30730082 30901271) 国家"十一五"艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2012ZX10002-003)
关键词 病毒性肝炎 乙型 乙型肝炎病毒 白细胞介素-21 Viral hepatitis typeB Hepatitis B virus Interleukin-21
  • 相关文献

参考文献14

二级参考文献35

  • 1姚光弼,任红,王宝恩,徐道振,周霞秋.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究[J].肝脏,2005,10(1):2-4. 被引量:66
  • 2姚光弼,张定凤,王宝恩,徐道振,周霞秋,雷秉钧.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究[J].中华肝脏病杂志,2005,13(7):484-487. 被引量:117
  • 3Jin H, Carrio R, Yu A, et al. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis [J]. J Immunol, 2004, 173(1): 657-665.
  • 4Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection [J]. Science, 2009, 324(5934): 1572-1576.
  • 5Rachel Ettinger, Gary P. Sims, Anna-Marie Fairhurst, et al. IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells[J]. J Immunol, 2005, 175(12): 7867-7869.
  • 6Pene J, Gauchat JF, Lecart S, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells [J]. J. Immunol, 2004, 172(9): 5154-5157.
  • 7Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B-cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5CF fol- hcular helper cells[J]. J Immunol, 2007, 179: 8180-8190.
  • 8Pene J, Guglielmi L, Gauchat JF, et al. IFN- γ mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene [J]. J Immunol, 2006, 177(8): 5006-5013.
  • 9Shang XZ, Ma KY, Radewonuk J, et al. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response [J]. Cell Immunol, 2006, 241(2): 66-74.
  • 10Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences [J]. N Engl J Med, 2004, 350(11): 1118-1129.

共引文献63

同被引文献46

  • 1Julian Bilous,Steven Wiersmg,王莉霞.世界卫生组织乙型肝炎控制目标和策略[J].中国计划免疫,2004,10(3):178-179. 被引量:25
  • 2王晓军,张荣珍,胡苑笙,梁晓峰.我国病毒性肝炎流行现状研究[J].疾病监测,2004,19(8):290-292. 被引量:150
  • 3张万华.乙型肝炎疫苗免疫低或无应答相关因素及策略的研究进展[J].右江医学,2006,34(3):310-312. 被引量:4
  • 4Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients [J]. J Gastroenterol Hepatol, 2011, 26 (3).. 456-460.
  • 5Song MJ, Song do S, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HI. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B [J]. World J Gastroenterol, 2012, 18 (43) .. 6277-6283.
  • 6Chen DB, Chen YM, Liu J, Xie DY, Lu CR, Huang ZL, Zhu RH, Gao ZL. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients [J]. J Clin Virol, 2014, 59(1).. 50-54.
  • 7Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim DY, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B [J]. Hepatology, 2010, 51(2): 415-421.
  • 8Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients [J]. J Clin Virol, 2010, 48(1): 22-26.
  • 9Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides [J]. Aliment Pharmacol Ther, 2014, 40(7): 804-810.
  • 10Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment [J]. J Hepatol, 2014, 61(3): 515-522.

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部